查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984024

人工智慧在製药市场的应用：按组件、技术、治疗领域、应用、部署模式和最终用户划分——2026年至2032年全球市场预测

Artificial Intelligence in Pharmaceutical Market by Component, Technology, Therapeutic Area, Applications, Deployment Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，医药产业的人工智慧 (AI) 市场价值为 200.8 亿美元，预计到 2026 年将成长至 255.4 亿美元，复合年增长率为 27.68%，到 2032 年将达到 1,111.3 亿美元。

主要市场统计数据
基准年 2025 200.8亿美元
预计年份：2026年 255.4亿美元
预测年份 2032 1111.3亿美元
复合年增长率 (%) 27.68%

策略实施：概述人工智慧如何改变药物研究、临床操作、监管流程、生产工作流程和商业策略。

人工智慧不再是製药营运中的实验性辅助手段，而是涵盖药物发现、临床开发、监管策略、生产营运和商业性决策等各环节的关键策略能力。在这种应用模式下，人工智慧不再只是一系列技术的集合，而是一股系统级力量，它重塑了药物整个生命週期中的知识创造、自动化决策和风险管理。因此，相关人员需要从多个观点看待人工智慧：将其视为药物发现中假设产生的加速器、患者筛选和临床试验优化的精准工具、监管合规的分析引擎，以及支撑供应链韧性的营运驱动力。

详细概述了透过人工智慧重新定义药物发现、临床试验设计、监管参与、生产製造和病人参与的变革性技术和组织变革。

製药业正经历一场由技术突破、组织思维转变和外部政策影响共同驱动的变革。在技术水准，模型架构、训练方法和领域自适应演算法的进步正在拓展自动化和预测的边界。卷积类神经网路、生成对立网路、循环神经网路和变压器等深度学习创新技术正日益与监督学习、无监督学习和强化学习等可操作的机器学习方法相结合，以解决复杂的生物医学问题。同时，影像分割、医学影像应用和目标检测等电脑视觉技术正在为诊断和临床前分析开闢新的途径，而自然语言处理则能够透过情感分析、语音辨识和文字探勘等技术，从临床记录、监管申报文件和文献中提取可操作的见解。

对 2025 年美国实施的关税措施对人工智慧驱动的药品供应链、跨境采购、製造投入和合作模式的累积影响进行重点分析。

2025年推出的关税环境进一步增加了人工智慧驱动型製药企业在采购、供应链规划和跨国合作方面的复杂性。影响硬体进口、试剂采购、临床设备和软体许可的关税措施可能会对整个生态系统产生连锁反应。例如，提高专用运算硬体和实验室设备的关税可能会增加本地部署的总拥有成本，从而使能够外包运算风险的云端解决方案获得财务优势。相反，针对特定SaaS模式或捆绑解决方案的关税可能会促使采购方向转向模组化架构和在地化服务模式。

整合细分洞察，解释人工智慧在製药业的应用和价值创造是如何由组件、技术系列、治疗领域、应用领域、部署模式和最终用户画像共同决定的。

要了解人工智慧将在製药业的哪些领域以及如何创造价值，必须整合影响部署模式和结果的多个细分维度。按组件划分，市场由“服务”和“软体”组成，“服务”又可细分为“託管服务”和“专业服务”，而“软体”则包括临床试验管理软体、诊断软体、药物发现平台、法规遵从工具和供应链管理软体。这种组件层面的观点表明，在实际部署中，软体平台通常与实施和託管支援相结合，以确保效能符合监管标准并维持营运连续性。

全面深入的区域分析，比较美洲、欧洲、中东、非洲和亚太地区的策略驱动因素、监管环境、投资趋势、基础设施发展和商业性采用模式。

区域趋势正显着影响人工智慧在整个医药价值链中的应用和推广，美洲、欧洲、中东、非洲和亚太地区呈现出截然不同的模式。在美洲，稳健的私营部门投资环境、先进的云端基础设施和成熟的创投生态系统正在加速平台开发和商业部署。同时，特定司法管辖区的监管指导正转向基于结果的检验，并建立更清晰的医疗设备软体框架。这为拥有快速迭代开发能力和强大证据生成能力的公司创造了有利环境。

本报告提供企业洞察，重点在于推动医药创新的关键人工智慧参与者的竞争定位、伙伴关係策略、产品和服务组合、平台差异化和市场进入方式。

医药人工智慧生态系统中的企业行为展现出清晰的策略模式。这些模式包括：平台提供者投资于端到端的产品套件；专注于特定高价值应用场景的专业演算法开发人员；将领域专业知识与可扩展实施方案相结合的系统整合商；以及将人工智慧能力融入外包开发服务的合约研究组织（CRO）。主要企业透过检验的数据资产、规范的工作流程以及降低生命科学客户整合摩擦的能力来脱颖而出。

为高阶主管提供可操作的策略建议，以加速负责任的人工智慧应用，优先考虑管治、人才发展、生态系统伙伴关係、平台选择和跨部门监管合规。

致力于加速负责任且策略性地应用人工智慧的产业领导者应将管治、人才、技术和伙伴关係关係有机地整合起来。首先，应建立跨职能管治，明确模型开发、检验、部署和监控的职责。此管治结构应整合法律、监管、临床和技术等相关人员，并制定标准化的检验通讯协定和审计追踪，以满足监管机构和内部风险管理部门的要求。同时，应投资于人才发展项目，将产业专长与资料科学技能结合。轮调计画、将资料科学家长期安置在治疗团队中，以及策略性地招募精通监管的机器学习工程师，都能缩短回馈週期，并提高演算法与临床目标的契合度。

透明的调查方法，说明了资料来源、相关人员访谈、与技术分类系统的一致性、治疗领域的映射、检验过程以及用于得出结论的分析框架。

本报告的结论和见解基于多方面的研究方法，结合了第一手和第二手研究、专家访谈以及针对技术和治疗领域的分类，确保其适用于任何决策情境。资料收集包括与涵盖製药公司、生物技术公司、合约研究组织 (CRO)、临床研究人员、监管专家和技术供应商等跨学科相关人员的结构化讨论，检验了实际限制、推荐的检验策略和部署模型。第二手资讯来源包括同行评审文献、监管指导文件、医疗设备软体标准以及可作为模型架构和检验方法参考的公开技术资讯。

简洁的结论整合了对研发、临床营运、监管策略、商业部署和供应链韧性的见解，同时强调了管治、技能和协作的必要性。

这些分析综合起来，凸显了一个战略现实：人工智慧 (AI) 如今已成为製药公司提升研发效率、简化临床试验、加强监管合规性以及优化供应链韧性的基础能力。在这个时代，成功的关键不在于盲目追逐每项技术创新，而是将 AI 投资与临床和监管的优先事项及规范相契合，并建立严格的检验方法和稳健的营运管治。那些将特定领域模型开发与提供互补数据、实验室自动化和实施专业知识的伙伴关係相结合的组织，将能够更快地从原型阶段过渡到实际营运阶段。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 医药市场：依成分划分

  • 服务
    • 託管服务
    • 专业服务
  • 软体
    • 临床试验管理软体
    • 诊断软体
    • 药物发现平台
    • 监理合规工具
    • 供应链管理软体

第九章 医药市场：依技术划分

  • 电脑视觉
    • 影像分割
    • 医学影像
    • 目标侦测
  • 深度学习
    • 卷积类神经网路
    • 生成性衝突网络
    • 递迴神经网
    • 变压器
  • 机器学习
    • 强化学习
    • 监督式学习
    • 无监督学习
  • 自然语言处理
    • 情绪分析
    • 语音辨识
    • 文字探勘
  • 机器人流程自动化

第十章：医药市场：依治疗领域划分

  • 心血管疾病
  • 免疫学
  • 感染疾病
  • 代谢性疾病
  • 神经病学
  • 肿瘤学
  • 呼吸系统疾病

第十一章 医药市场：依应用领域划分

  • 临床试验
    • 临床数据管理
    • 病患招募
    • 预测分析
    • 基于风险的监测
  • 药物发现
    • 药物发现
    • 最终模型的检验
    • 先导药物最适化
    • 目标选择
  • 个性化医疗保健
    • 生物标记发现
    • 基因组分析
    • 精准医疗发展
  • 供应链管理
    • 需求预测
    • 库存管理
    • 物流最佳化

第十二章 医药市场：依开发类型划分

  • 基于云端的
  • 现场

第十三章 医药市场：依最终用户划分

  • 学术和研究机构
  • 合约研究组织（CRO）
  • 製药和生物技术公司

第十四章 医药市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 医药市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 药品市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国医药市场

第十八章：中国医药市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AiCure, LLC
  • Aspen Technology Inc.
  • Atomwise Inc.
  • BenevolentAI SA
  • BioSymetrics Inc.
  • BPGbio Inc.
  • Butterfly Network, Inc.
  • Cloud Pharmaceuticals, Inc.
  • Cyclica by Recursion Pharmaceuticals, Inc.
  • Deargen Inc.
  • Deep Genomics Incorporated
  • Deloitte Touche Tohmatsu Limited
  • Euretos Services BV
  • Exscientia PLC
  • Insilico Medicine
  • Intel Corporation
  • International Business Machines Corporation
  • InveniAI LLC
  • Isomorphic Labs Limited
  • Microsoft Corporation
  • Novo Nordisk A/S
  • NVIDIA Corporation
  • Oracle Corporation
  • SANOFI WINTHROP INDUSTRIE
  • Turbine Ltd.
  • Viseven Europe OU
  • XtalPi Inc.
Product Code: MRR-A6768A62EE00

The Artificial Intelligence in Pharmaceutical Market was valued at USD 20.08 billion in 2025 and is projected to grow to USD 25.54 billion in 2026, with a CAGR of 27.68%, reaching USD 111.13 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 20.08 billion
Estimated Year [2026] USD 25.54 billion
Forecast Year [2032] USD 111.13 billion
CAGR (%) 27.68%

A strategic introduction outlining how artificial intelligence is reshaping pharmaceutical research, clinical operations, regulatory pathways, manufacturing workflows, and commercial strategies

Artificial intelligence is no longer an experimental adjunct in pharmaceutical workstreams; it has become an integral strategic capability that touches discovery science, clinical development, regulatory strategy, manufacturing operations, and commercial decision-making. This introduction frames AI not merely as a set of technologies but as a system-level force reshaping how knowledge is generated, decisions are automated, and risks are managed across the lifecycle of medicines. Stakeholders must therefore view AI through multiple lenses: as an accelerant for hypothesis generation in drug discovery, as a precision tool for patient identification and trial optimization, as an analytics engine for regulatory compliance, and as an operational enabler for supply chain resilience.

To navigate this environment, leaders must appreciate three converging dynamics. First, advances in compute, data infrastructure, and model architectures are broadening the range of tractable problems. Second, the maturation of domain-specific platforms and validated workflows is lowering integration friction for research and clinical teams. Third, regulatory and ethical expectations are co-evolving with capabilities, increasing the importance of reproducibility, explainability, and robust validation. As a result, AI adoption in pharmaceuticals is increasingly driven by outcome-oriented deployments that emphasize measurable improvements in cycle time, quality, and patient-centricity rather than technology for its own sake.

This introductory analysis sets the stage for deeper examination by emphasizing practical implications for R&D leaders, clinical operations directors, regulatory strategists, manufacturing heads, and commercial executives. It establishes the imperative for cross-functional governance, a clear technology- and data-integration roadmap, and an investment posture that balances platform development with targeted proof-of-concept initiatives. In short, organizations that align technical capability with clinical and regulatory objectives are positioned to capture disproportionate value as AI transitions from novelty to operational backbone.

A detailed synthesis of transformative technological and organizational shifts that are redefining drug discovery, trial design, regulatory interactions, manufacturing, and patient engagement through AI

The pharmaceutical landscape is undergoing transformative shifts driven by technological breakthroughs, shifting organizational mindsets, and external policy influences. At the technology level, advances in model architectures, training regimes, and domain-adapted algorithms are expanding the frontier of what can be automated and predicted. Deep learning innovations in convolutional neural networks, generative adversarial networks, recurrent neural networks, and transformers are increasingly coupled with pragmatic machine learning approaches such as supervised and unsupervised learning plus reinforcement learning to address complex biomedical problems. In parallel, computer vision capabilities including image segmentation, medical imaging applications, and object detection are unlocking new modalities for diagnostics and preclinical assay analysis, while natural language processing is enabling extraction of actionable insights from clinical notes, regulatory submissions, and literature through techniques such as sentiment analysis, speech recognition, and text mining.

Organizationally, there is a clear shift from isolated proofs of concept to scaled deployments that integrate software and service offerings. Component-level segmentation illustrates that software domains-ranging from clinical trial management platforms and diagnostic tools to drug discovery platforms, regulatory compliance tools, and supply chain management solutions-are being complemented by services ecosystems that include managed and professional services. This integration of services and software is accelerating time-to-value by combining technical implementation with domain expertise. Simultaneously, application domains such as clinical trials, drug discovery, personalized healthcare, and supply chain optimization are maturing; clinical trial automation is extending into patient recruitment, clinical data management, predictive analytics, and risk-based monitoring, while drug discovery workflows are embracing computational drug design, lead optimization, target selection, and end-model validation.

These shifts are also reshaping talent and partnership strategies. Life sciences organizations are investing in cross-disciplinary teams that combine biomedical scientists, data engineers, and regulatory specialists. Contract research organizations and technology vendors are forming deeper alliances with pharmaceutical companies to co-develop validated workflows and to ensure reproducibility. Taken together, these technical and organizational transformations are creating a new competitive dynamic where speed, rigor, and regulatory-aligned validation are the primary differentiators.

A focused analysis of the cumulative effects of United States tariff measures enacted in 2025 on AI-enabled pharmaceutical supply chains, cross-border sourcing, manufacturing inputs, and collaboration models

The tariff landscape introduced in 2025 has introduced additional complexity into procurement, supply chain planning, and cross-border collaboration for AI-enabled pharmaceutical operations. Tariff measures that affect hardware imports, reagent sourcing, clinical instrumentation, and software licensing can create ripple effects across the ecosystem. For example, increases in duties on specialized computing hardware or laboratory instrumentation raise the total cost of ownership for on-premises deployments and may tilt the economics in favor of cloud-based solutions where compute risks can be externalized. Conversely, tariffs that target certain software-as-a-service models or bundled solutions can shift procurement preferences toward modular architectures and localized service models.

Beyond direct cost impacts, tariffs affect supplier selection and sourcing strategies. Organizations respond by diversifying supplier bases, accelerating qualification of alternative vendors, and re-evaluating regional manufacturing footprints to mitigate exposure to trade policy shifts. These adjustments often influence timelines for validation and regulatory filings, because change controls associated with new suppliers or different equipment can introduce additional documentation burdens. In addition, tariffs can influence investment decisions in nearshoring or reshoring initiatives, where companies seek to reduce cross-border dependencies for critical components or biologics manufacturing inputs.

Moreover, tariffs have implications for collaborative research and data-sharing arrangements across borders. Increased customs scrutiny and shifting import regimes can complicate the transport of biological samples, specialized reagents, and equipment essential for collaborative trials. For multinational programs, sponsors may need to redesign logistics corridors, re-assess third-party provider contracts, and update risk registers to reflect tariff-induced delays. In response, savvy organizations are prioritizing supply chain visibility, multi-source qualification, and contractual flexibility as part of their operational resilience programs. While tariffs do not alter the scientific feasibility of AI applications, they meaningfully affect the operational pathways through which those applications are deployed and scaled.

Integrated segmentation insights explaining how components, technology families, therapeutic focus areas, application domains, deployment models, and end-user profiles jointly determine AI uptake and value creation in pharma

Understanding where and how AI generates value in pharmaceuticals requires an integrated view of multiple segmentation axes that together shape adoption patterns and outcomes. Based on Component, the landscape comprises Services and Software where Services splits into Managed Services and Professional Services and Software includes clinical trial management software, diagnostic software, drug discovery platforms, regulatory compliance tools, and supply chain management software. This component-level view clarifies that practical deployments frequently combine software platforms with implementation and managed support to ensure regulatory-grade performance and operational continuity.

Based on Technology, adopters must evaluate capabilities across computer vision, deep learning, machine learning, natural language processing, and robotic process automation; within these families there are important sub-specializations such as image segmentation, medical imaging, and object detection for computer vision, convolutional neural networks, generative adversarial networks, recurrent neural networks, and transformers for deep learning, and reinforcement learning, supervised learning, and unsupervised learning for machine learning, alongside sentiment analysis, speech recognition, and text mining for NLP. The multiplicity of approaches underscores the need for a technology taxonomy that maps each method to specific use cases and validation requirements.

Based on Therapeutic Area, AI initiatives often align with clinical priority and data maturity across cardiovascular diseases, immunology, infectious diseases, metabolic diseases, neurology, oncology, and respiratory diseases. Disease biology, endpoint definability, and data availability vary across these areas, which in turn affects algorithmic approachability and regulatory scrutiny. Based on Applications, deployment domains include clinical trials, drug discovery, personalized healthcare, and supply chain management with clinical trials subdividing into clinical data management, patient recruitment, predictive analytics, and risk-based monitoring, while drug discovery encompasses drug design, end-model validation, lead optimization, and target selection and personalized healthcare covers biomarker discovery, genomic profiling, and precision medicine development and supply chain management focuses on demand forecasting, inventory management, and logistics optimization.

Based on Deployment Type, choices between cloud-based and on-premises architectures have implications for data governance, latency, and cost structure, and based on End User, the primary consumers of these solutions span academic and research institutions, contract research organizations, and pharmaceutical and biotechnology companies. The intersections among these segmentation axes create contextual trade-offs: for example, oncology discovery efforts may preferentially adopt deep learning generative models and on-premises deployments when patient-level privacy and validation are paramount, while supply chain optimization workstreams commonly leverage cloud-based machine learning and managed services to maximize elasticity and cross-site visibility. Therefore, segmentation-aware strategies are essential to align technical design, validation planning, procurement strategy, and organizational capability development.

Comprehensive regional insights comparing strategic drivers, regulatory landscapes, investment trends, infrastructure readiness, and commercial adoption patterns across Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics exert a strong influence on how AI is adopted and scaled across the pharmaceutical value chain, with distinctive patterns emerging across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, a robust private sector investment environment, advanced cloud infrastructure, and established venture ecosystems have accelerated platform development and commercial deployments, while regulatory guidance in certain jurisdictions has moved toward outcomes-based validation and clearer frameworks for software as a medical device. This creates a favorable environment for companies that combine rapid iteration with strong evidence-generation capabilities.

In Europe, Middle East & Africa, regulatory rigor and data protection regimes shape design and deployment choices, often increasing the emphasis on explainability, localized data residency, and formalized validation paths. National policy initiatives and pan-European collaborations have also fostered consortium-based models for data sharing that enable multicenter trials and federated learning approaches. Meanwhile in parts of the Middle East and Africa, infrastructural variability and nascent data ecosystems require bespoke implementation models and capacity-building partnerships.

Asia-Pacific presents a heterogeneous but highly dynamic set of conditions where strong manufacturing clusters, rapidly growing clinical trial activity, and sizable patient populations create compelling use cases for AI. Several markets in the region are advancing digital health policies and public-private partnerships that accelerate deployment of diagnostic and clinical decision-support tools. Importantly, regional supply chain integration, proximity to key hardware suppliers, and an expanding talent base make Asia-Pacific an attractive locus for both development and scaled implementation projects. Across all regions, local regulatory expectations, talent availability, data governance frameworks, and infrastructure maturity determine the optimal mix of cloud versus on-premises deployment and the most effective partnership models for vendors and sponsors alike.

Company insights emphasizing competitive positioning, partnership strategies, product and service portfolios, platform differentiation, and go-to-market approaches among leading AI players supporting pharmaceutical innovation

Company behavior in the AI-for-pharma ecosystem demonstrates distinct strategic archetypes, including platform providers that invest in end-to-end product suites, specialized algorithm developers focusing on narrow high-value use cases, systems integrators that bridge domain expertise with scalable implementation, and contract research organizations that embed AI capabilities into outsourced development services. Leading organizations are differentiating through validated data assets, regulatory-compliant workflows, and capabilities that reduce integration friction for life sciences customers.

Across supplier strategies, we observe three persistent patterns. The first is platform consolidation where vendors expand horizontally to offer clinical trial, discovery, and compliance modules that interoperate within a single architecture. The second is vertical specialization where niche players concentrate on a therapeutic or modality-specific problem-such as imaging in oncology or genomic profiling in personalized medicine-and achieve deep validation within that domain. The third pattern is partnership ecosystems where companies join forces to combine proprietary algorithms, clinical data, and laboratory automation in order to deliver regulated outcomes.

From a procurement perspective, pharmaceutical and biotechnology customers increasingly evaluate vendors on evidence of real-world performance, regulatory readiness, and post-deployment support capabilities, rather than on feature checklists alone. As a result, successful companies prioritize clinical validation studies, transparent model governance, and comprehensive professional or managed services to ensure sustained operational performance. Contracts reflect these expectations with outcomes-linked milestones, change-control provisions, and clear responsibilities for data stewardship and model maintenance.

Actionable strategic recommendations for executives to accelerate responsible AI adoption by prioritizing governance, talent development, ecosystem partnerships, platform selection, and regulatory alignment across functions

Industry leaders seeking to accelerate responsible and strategic AI adoption should pursue a coherent mix of governance, talent, technology, and partnership actions. Begin by establishing cross-functional governance that assigns clear accountability for model development, validation, deployment, and monitoring; governance structures should integrate legal, regulatory, clinical, and technical stakeholders and define standardized validation protocols and audit trails to satisfy regulators and internal risk functions. Simultaneously, invest in talent programs that blend domain expertise with data science skills; rotational programs, embedded data scientists within therapeutic teams, and strategic hiring of regulatory-savvy machine learning engineers will shorten feedback loops and improve the alignment of algorithms with clinical objectives.

On the technology front, prioritize modular architectures that balance the benefits of cloud-based scalability with the control afforded by on-premises deployments where privacy or latency constraints demand it. Adopt open and transparent model governance practices, including versioning, reproducibility tests, and clear explainability artifacts tied to clinical endpoints. In parallel, develop an ecosystem strategy that differentiates between capabilities to build internally and those best accessed through partnerships with academic centers, CROs, or specialized vendors. Structured collaborations with contract research organizations can accelerate trial execution, while alliances with diagnostic firms and lab automation providers can de-risk end-to-end implementation.

Finally, align procurement and contracting approaches with performance-based outcomes and continuous validation requirements. Include provisions for post-deployment monitoring, change management, and retraining cycles in vendor agreements. Taken together, these steps provide a pragmatic roadmap for leaders to scale AI responsibly while delivering measurable clinical and operational improvements.

A transparent research methodology describing data sources, stakeholder interviews, technology taxonomy alignment, therapeutic mapping, validation processes, and analytical frameworks used to generate conclusions

The conclusions and insights in this report are grounded in a multi-method research approach combining primary and secondary evidence, expert interviews, and a technology- and therapeutic-focused taxonomy to ensure applicability across decision contexts. Data collection included structured discussions with interdisciplinary stakeholders across pharmaceutical companies, biotechnology firms, contract research organizations, clinical investigators, regulatory specialists, and technology vendors to validate practical constraints, preferred validation strategies, and deployment models. Secondary inputs comprised peer-reviewed literature, regulatory guidance documents, standards for software as a medical device, and public technical disclosures that inform model architectures and validation practices.

Analytically, the work uses a taxonomy that maps component types, technology families, therapeutic priorities, application domains, deployment models, and end-user segments to observed adoption patterns and implementation risks. Validation exercises included cross-referencing interview findings with documented case studies and technology white papers, and applying scenario analysis to explore the operational consequences of supply chain disruptions and policy changes. Quality assurance measures involved iterative peer review, triangulation of evidence across sources, and explicit documentation of assumptions and limitations. This methodology ensures that recommendations are traceable to observable practices and that the analytical framework remains adaptable to evolving regulatory and technical developments.

A concise conclusion synthesizing implications for R&D, clinical operations, regulatory strategy, commercial deployment, and supply chain resilience while emphasizing governance, skills, and collaboration imperatives

The cumulative analysis underscores a singular strategic reality: artificial intelligence is now a foundational capability for pharmaceutical organizations that seek to improve R&D productivity, enhance clinical trial efficiency, strengthen regulatory compliance, and optimize supply chain resilience. Success in this era depends not on chasing every technical novelty but on disciplined alignment of AI investments with clinical and regulatory priorities, rigorous validation practices, and robust operational governance. Organizations that combine domain-focused model development with partnerships that supply complementary data, lab automation, and implementation expertise will move faster from prototype to production.

Moreover, the interplay between policy levers-such as tariffs and data governance regimes-and operational execution highlights the need for continuous risk assessment and adaptive sourcing strategies. Effective deployment requires a pragmatic mix of cloud and on-premises approaches informed by privacy constraints and latency considerations, and contracting models that emphasize outcomes and post-deployment stewardship. Ultimately, building sustained advantage with AI in pharmaceuticals is a multi-year endeavor that hinges on reproducibility, explainability, and the capacity to learn from real-world performance. Executives who prioritize these elements will be positioned to convert technical capability into measurable clinical and business results.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Artificial Intelligence in Pharmaceutical Market, by Component

  • 8.1. Services
    • 8.1.1. Managed Services
    • 8.1.2. Professional Services
  • 8.2. Software
    • 8.2.1. Clinical Trial Management Software
    • 8.2.2. Diagnostic Software
    • 8.2.3. Drug Discovery Platforms
    • 8.2.4. Regulatory Compliance Tools
    • 8.2.5. Supply Chain Management Software

9. Artificial Intelligence in Pharmaceutical Market, by Technology

  • 9.1. Computer Vision
    • 9.1.1. Image Segmentation
    • 9.1.2. Medical Imaging
    • 9.1.3. Object Detection
  • 9.2. Deep Learning
    • 9.2.1. Convolutional Neural Networks
    • 9.2.2. Generative Adversarial Networks
    • 9.2.3. Recurrent Neural Networks
    • 9.2.4. Transformers
  • 9.3. Machine Learning
    • 9.3.1. Reinforcement Learning
    • 9.3.2. Supervised Learning
    • 9.3.3. Unsupervised Learning
  • 9.4. Natural Language Processing
    • 9.4.1. Sentiment Analysis
    • 9.4.2. Speech Recognition
    • 9.4.3. Text Mining
  • 9.5. Robotic Process Automation

10. Artificial Intelligence in Pharmaceutical Market, by Therapeutic Area

  • 10.1. Cardiovascular Diseases
  • 10.2. Immunology
  • 10.3. Infectious Diseases
  • 10.4. Metabolic Diseases
  • 10.5. Neurology
  • 10.6. Oncology
  • 10.7. Respiratory Diseases

11. Artificial Intelligence in Pharmaceutical Market, by Applications

  • 11.1. Clinical Trials
    • 11.1.1. Clinical Data Management
    • 11.1.2. Patient Recruitment
    • 11.1.3. Predictive Analytics
    • 11.1.4. Risk-Based Monitoring
  • 11.2. Drug Discovery
    • 11.2.1. Drug Design
    • 11.2.2. End-Model Validation
    • 11.2.3. Lead Optimization
    • 11.2.4. Target Selection
  • 11.3. Personalized Healthcare
    • 11.3.1. Biomarker Discovery
    • 11.3.2. Genomic Profiling
    • 11.3.3. Precision Medicine Development
  • 11.4. Supply Chain Management
    • 11.4.1. Demand Forecasting
    • 11.4.2. Inventory Management
    • 11.4.3. Logistics Optimization

12. Artificial Intelligence in Pharmaceutical Market, by Deployment Type

  • 12.1. Cloud-Based
  • 12.2. On-Premises

13. Artificial Intelligence in Pharmaceutical Market, by End User

  • 13.1. Academic and Research Institutions
  • 13.2. Contract Research Organizations (CROs)
  • 13.3. Pharmaceutical & Biotechnology Companies

14. Artificial Intelligence in Pharmaceutical Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Artificial Intelligence in Pharmaceutical Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Artificial Intelligence in Pharmaceutical Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Artificial Intelligence in Pharmaceutical Market

18. China Artificial Intelligence in Pharmaceutical Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AiCure, LLC
  • 19.6. Aspen Technology Inc.
  • 19.7. Atomwise Inc.
  • 19.8. BenevolentAI SA
  • 19.9. BioSymetrics Inc.
  • 19.10. BPGbio Inc.
  • 19.11. Butterfly Network, Inc.
  • 19.12. Cloud Pharmaceuticals, Inc.
  • 19.13. Cyclica by Recursion Pharmaceuticals, Inc.
  • 19.14. Deargen Inc.
  • 19.15. Deep Genomics Incorporated
  • 19.16. Deloitte Touche Tohmatsu Limited
  • 19.17. Euretos Services BV
  • 19.18. Exscientia PLC
  • 19.19. Insilico Medicine
  • 19.20. Intel Corporation
  • 19.21. International Business Machines Corporation
  • 19.22. InveniAI LLC
  • 19.23. Isomorphic Labs Limited
  • 19.24. Microsoft Corporation
  • 19.25. Novo Nordisk A/S
  • 19.26. NVIDIA Corporation
  • 19.27. Oracle Corporation
  • 19.28. SANOFI WINTHROP INDUSTRIE
  • 19.29. Turbine Ltd.
  • 19.30. Viseven Europe OU
  • 19.31. XtalPi Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MANAGED SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MANAGED SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MANAGED SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROFESSIONAL SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROFESSIONAL SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PROFESSIONAL SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIAL MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DIAGNOSTIC SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGULATORY COMPLIANCE TOOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGULATORY COMPLIANCE TOOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGULATORY COMPLIANCE TOOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMAGE SEGMENTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMAGE SEGMENTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMAGE SEGMENTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MEDICAL IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MEDICAL IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MEDICAL IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OBJECT DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OBJECT DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY OBJECT DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONVOLUTIONAL NEURAL NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENERATIVE ADVERSARIAL NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENERATIVE ADVERSARIAL NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENERATIVE ADVERSARIAL NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RECURRENT NEURAL NETWORKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TRANSFORMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TRANSFORMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TRANSFORMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REINFORCEMENT LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REINFORCEMENT LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REINFORCEMENT LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY UNSUPERVISED LEARNING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY UNSUPERVISED LEARNING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY UNSUPERVISED LEARNING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SENTIMENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SENTIMENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SENTIMENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SPEECH RECOGNITION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SPEECH RECOGNITION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SPEECH RECOGNITION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TEXT MINING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TEXT MINING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TEXT MINING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ROBOTIC PROCESS AUTOMATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY METABOLIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY METABOLIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RESPIRATORY DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RESPIRATORY DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL DATA MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT RECRUITMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT RECRUITMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PATIENT RECRUITMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PREDICTIVE ANALYTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PREDICTIVE ANALYTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PREDICTIVE ANALYTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RISK-BASED MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RISK-BASED MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY RISK-BASED MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DESIGN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DESIGN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DESIGN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END-MODEL VALIDATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END-MODEL VALIDATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END-MODEL VALIDATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LEAD OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LEAD OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LEAD OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TARGET SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TARGET SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TARGET SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENOMIC PROFILING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENOMIC PROFILING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY GENOMIC PROFILING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRECISION MEDICINE DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRECISION MEDICINE DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PRECISION MEDICINE DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEMAND FORECASTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEMAND FORECASTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEMAND FORECASTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INVENTORY MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INVENTORY MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY INVENTORY MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LOGISTICS OPTIMIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LOGISTICS OPTIMIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY LOGISTICS OPTIMIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLOUD-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ON-PREMISES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ON-PREMISES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ON-PREMISES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS (CROS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 190. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 191. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 192. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 193. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 194. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 196. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 197. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 198. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 199. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 200. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 201. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 202. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 203. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 204. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 205. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. AMERICAS ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 208. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 210. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 214. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 216. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 218. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 220. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 222. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 226. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 228. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 230. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 232. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 234. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 236. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED HEALTHCARE, 2018-2032 (USD MILLION)
  • TABLE 238. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUPPLY CHAIN MANAGEMENT, 2018-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEPLOYMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. LATIN AMERICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPONENT, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SERVICES, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY SOFTWARE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY COMPUTER VISION, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DEEP LEARNING, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY MACHINE LEARNING, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY THERAPEUTIC AREA, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY APPLICATIONS, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY CLINICAL TRIALS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY DRUG DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL MARKET SIZE, BY PERSONALIZED